SurModics Inc (SRDX)

[Democritus_of_Abdera]

Octoplus Readme First

Surmodics’ Investment in OctoPlus (OCTO)

#msg-12959885 (08/28/06): Introduction of OCTO to the SRDX message board

#msg-13816009 (10/05/06): SRDX’s equity investment in OCTO (see also: #msg-13841250, #msg-12958080)

#msg-17141398 (02/16/07): Listing of biodegradable polymers purchased by SRDX from OCTO (see also: #msg-12262367)

Locteron & OctoPlus’ Collaboration with Biolex

#msg-32919440 (10/16/08): Locteron is placed #3 on Dew’s list of HCV drugs most likely to succeed.

#msg-32924615 (10/06/08): OCTO’s agreement with Biolex regarding Locteron. Locteron combines OCTOs PolyActive® drug delivery technology with BLX-883, a recombinant alfa interferon produced by Biolex Therapeutics using transgenic-plant technology. (see also #msg-32662307; #msg-32662762, #msg-30621154)

#msg-15116312 (11/28/06): Description of Biolex’s technological advantages (see also: #msg-26942561, #msg-25179852, #msg-25183120)
#msg-21638503 (07/28/07): relationship between HGSI’s Albuferon and Locteron (see also: #msg-21637496, #msg-24371607, #msg-18342282)

#msg-28786162 (04/25/08): Phase-2a results for Locteron. (see also #msg-26612906; #msg-23627540, #msg-24304055, #msg-21566438, #msg-16610930)

#msg-30621180 (07/11/08): Dew’s list of posts regarding Biolex

OctoPlus Products

#msg-18341699 (03/30/07): OCTO’s pipeline.

#msg-19093576 (04/25/07): OCTOs acquisition of PolyActive drug delivery technology from IsoTis (see also #msg-19095262)

#msg-23219029 (09/27/07): OCTOs license of a GLP-1 agonist.

OctoPlus Reports

#msg-13828644 (10/06/06): Bridge posts a link to the OCTO prospectus.

#msg-17079056 (02/15/07): Dew summarizes OCTO 2006 results (see also: #msg-18338843)

#msg-21785811 (08/03/07): Dew posts OCTOs 1H07 results.

#msg-27020385 (02/22/08): Dew posts OCTOs 2H07 results.